Quick Answer
AN2 Therapeutics, Inc. reported Net Income Loss of -$35.17 million for the year ending 2025.
- AN2 Therapeutics, Inc. showed an increase of +31.5% in Net Income Loss from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.05 million | Q2 2021: -$5.01 million | Q3 2021: -$6.94 million | Q1 2022: -$7.66 million | Q2 2022: -$10.12 million | Q3 2022: -$11.34 million | Q1 2023: -$15.32 million | Q2 2023: -$15.80 million | Q3 2023: -$16.71 million | Q1 2024: -$16.62 million | Q2 2024: -$14.44 million | Q3 2024: -$12.75 million | Q1 2025: -$10.65 million | Q2 2025: -$6.46 million | Q3 2025: -$9.35 million.
- Over the full 5 years of available data (2021 to 2025), AN2 Therapeutics, Inc.'s Net Income Loss has declined by 63.3%.
- Historical annual values: Fiscal year 2025: -$35.17 million | Fiscal year 2024: -$51.32 million | Fiscal year 2023: -$64.73 million | Fiscal year 2022: -$40.96 million | Fiscal year 2021: -$21.54 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: